ProQR Therapeutics (PRQR) Stock Forecast, Price & News

ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

Is ProQR Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ProQR Therapeutics stock.
View analyst ratings for ProQR Therapeutics or view top-rated stocks.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 1,150,000 shares, a drop of 28.1% from the April 15th total of 1,600,000 shares. Based on an average daily volume of 2,030,000 shares, the short-interest ratio is currently 0.6 days. Approximately 2.1% of the company's shares are short sold.
View ProQR Therapeutics' Short Interest.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for ProQR Therapeutics.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) issued its earnings results on Thursday, February, 24th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04. The biopharmaceutical company earned $0.27 million during the quarter, compared to the consensus estimate of $0.90 million. ProQR Therapeutics had a negative net margin of 2,469.79% and a negative trailing twelve-month return on equity of 51.75%.
View ProQR Therapeutics' earnings history.

What price target have analysts set for PRQR?

8 analysts have issued 12 month target prices for ProQR Therapeutics' shares. Their forecasts range from $2.00 to $19.00. On average, they expect ProQR Therapeutics' stock price to reach $7.43 in the next year. This suggests a possible upside of 994.0% from the stock's current price.
View analysts' price targets for ProQR Therapeutics or view top-rated stocks among Wall Street analysts.

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the following people:

• Mr. Daniel Anton de Boer, Founder, CEO & Member of Management Board (Age 39, Pay $761.74k)
• Ms. Theresa Marie Heggie, Chief Operating Officer (Age 62, Pay $39.23k)
• Mr. Gerard Platenburg, Co-Founder & Chief Innovation Officer (Age 58)
• Ms. Smital Shah M.B.A., Chief Bus. & Financial Officer (Age 46)
• Dr. Naveed K. Shams M.D., Ph.D., Chief Scientific Officer (Age 66)
• Ms. Sarah Cue Kiely, VP of Investor Relations & Corp. Communications
• Ms. Sheila Sponselee, VP of HR
• Mr. Bart Klein, Sr. VP of Intellectual Property
• Ms. Bianca Matthee, Head of Manufacturing and Pharmaceutics
• Mr. Aniz Girach M.D., Chief Medical Officer (Age 55)

Who are some of ProQR Therapeutics' key competitors?

Some companies that are related to ProQR Therapeutics include Entrada Therapeutics (TRDA), Longeveron (LGVN), Nanobiotix (NBTX), Cogent Biosciences (COGT), Viking Therapeutics (VKTX), Theratechnologies (THERF), Athersys (ATHX), XBiotech (XBIT), Allakos (ALLK), IO Biotech (IOBT), Pliant Therapeutics (PLRX), Verrica Pharmaceuticals (VRCA), Vaccitech (VACC), Milestone Pharmaceuticals (MIST) and Rhythm Pharmaceuticals (RYTM).
View all of PRQR's competitors.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Privium Fund Management B.V. (10.45%), Wellington Management Group LLP (4.33%), M28 Capital Management LP (1.41%), JPMorgan Chase & Co. (1.37%), Goldman Sachs Group Inc. (1.09%) and Renaissance Technologies LLC (0.85%).

Which institutional investors are selling ProQR Therapeutics stock?

PRQR stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Gilder Gagnon Howe & Co. LLC, Wellington Management Group LLP, Belvedere Trading LLC, Mirae Asset Global Investments Co. Ltd., and Simplex Trading LLC.

Which institutional investors are buying ProQR Therapeutics stock?

PRQR stock was bought by a variety of institutional investors in the last quarter, including M28 Capital Management LP, Renaissance Technologies LLC, Privium Fund Management B.V., JPMorgan Chase & Co., Prosight Management LP, XTX Topco Ltd, Monaco Asset Management SAM, and BlackRock Inc..

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $0.68.

How much money does ProQR Therapeutics make?

ProQR Therapeutics has a market capitalization of $48.41 million and generates $1.60 million in revenue each year. The biopharmaceutical company earns $-72.90 million in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

ProQR Therapeutics employs 1,504 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is www.proqr.com.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at [email protected].